Opioid Facts and Figures, recorded 3-June-2022. Presented by Lauran Wirf, DO: Addiction Medicine Fellow; University of Colorado School of Medicine; Denver, Colorado. With the increasing prevalence of illicit fentanyl, it is important for healthcare providers to understand the new hurdles they may face in treatment of opioid use disorders.
The opioid crisis is a major public health challenge in the United States, killing about 70,000 people in 2020 alone. Long delays and feedbacks between policy actions and their effects on drug-use behavior create dynamic complexity, complicating policy decision-making.
Assessing the feasibility, usability and acceptability of the MySafeRx platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial
Increasing buprenorphine/naloxone (B/N) access for opioid use disorder (OUD) is essential yet ensuring adherence and preventing diversion remains challenging. This study examines the feasibility, usability, and acceptability of MySafeRx, a mobile platform integrating motivational coaching, adherence monitoring, and electronic dispensing during office-based B/N treatment.
Presented by Kristin Waite-Labott, RN, BSN, CARN; April Lynn Lenzmeier, RN, DNP; Rachel Shuster, BSN, RN, CARN, CAAP. The American Nurses Association estimates that six to eight percent of nurses use alcohol or drugs to an extent that is sufficient to impair professional performance. Others estimate that nurses generally misuse drugs and alcohol at nearly the same rate (10 to 15 percent) as the rest of the population.
Promoting sustainable responses to the US opioid epidemic with community-academic partnerships: qualitative outcomes from a statewide program
Drug overdose deaths in the United States have continued to increase at an alarming rate. The Substance Abuse and Mental Health Services Administration (SAMHSA) distributed more than $7 billion between January 2016 and June 2020 to address the drug overdose crisis.
Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
Medication treatment for opioid use disorder (OUD) (MOUD; buprenorphine and methadone) reduces opioid use and overdose. Discontinuation of MOUD can quickly lead to relapse, overdose and death. Few persons who initiate MOUD are retained on treatment, thus it is critical to identify factors associated with retention.
Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors
Importance Some selective serotonin reuptake inhibitors (SSRIs) inhibit the enzymes responsible for the metabolism of oxycodone, a potent prescription opioid. The clinical consequences of this interaction on the risk of opioid overdose have not been elucidated.
Document of the Ministry of Health and Social Protection of Colombia that presents baseline of the maintenance programs with methadone in the country and the profile of the population served and the general characteristics of the treatment, as well as recommendations in public health for the strengthening of these programs.